Fresenius Medical Care AG & Co. KGAA booked second-quarter net income attributable to shareholders of €269 million, or 88 cents per share, up from €264 million, or 86 cents per share, the previous year.
Revenue for the quarter was up 8.8% on a constant currency basis to €4.47 billion from €4.03 billion in the corresponding quarter of 2016.
For the first half of 2017, the German company saw a 10.5% jump in revenue to €9.02 billion from €7.94 billion in the year-ago period. Net income attributable to shareholders for the half increased by 18.5% to €577 million, or €1.88 per share, up from €477 million, or €1.56 per share, in 2016.
Research and development costs for the six months ended June 30 reached €67 million, down 1.7% from the same period last year.
The company confirmed its full-year outlook for 2017, which was a 7% to 9% year-over-year increase in net income attributable to shareholders and revenue growth between 8% and 10% on a constant currency basis. The outlook excludes the effects of Fresenius Medical Care's agreements with the U.S. Department of Veterans Affairs and the U.S. Department of Justice.